Pacer Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Pacer Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Buy	+1,633	New	+$34K	﹤0.01%	2116
2024 Q3	–	Sell	-1,012	Closed	-$20.8K	–	2685
2024 Q2	$20.8K	Sell	1,012 -722	-42%	-$15.1K	﹤0.01%	3425
2024 Q1	$41.3K	Buy	+1,734	New	+$38.7K	﹤0.01%	3246
2021 Q2	–	Sell	-3,402	Closed	-$76K	–	1542
2021 Q1	$76K	Buy	3,402 +866	+34%	+$19.6K	﹤0.01%	1340
2020 Q4	$56K	Buy	+2,536	New	+$52.6K	﹤0.01%	1406

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Pacer Advisors's SNDX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 1,633 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #2116 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in SNDX as recently as Q2 2024.

Pacer Advisors first reported a position in SNDX in Q4 2020 and has held it in 5 quarters since. The position peaked at $76K in Q1 2021. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Pacer Advisors held 1,633 shares of Syndax Pharmaceuticals worth $36K as of Q2 2026.
Syndax Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2116 holding.
Pacer Advisors first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
Pacer Advisors's Syndax Pharmaceuticals position peaked at $76K in Q1 2021.
243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.